Table 1

Baseline demographic, clinical, functional, and x-ray characteristics of patients

Low disease activity (BASDAI < 4) (n = 5)

High disease activity (BASDAI ≥ 4) (n = 7)


Males/females

4/1

3/4

HLA-B27-positive, percentage

100

57

Age, years

31.0 (25-50)

41.0 (24-56)

Duration since diagnosisa, years

2.0 (0-4)

3.0 (0-20)

Duration of symptomsb, years

12.0 (7-19)

12.0 (1-32)

BASDAI (0-10)

1.7 (0.7-2.2)

6.9 (5.1-9.8)

ESR, mm/hour

14.0 (4-19)

23.0 (2-30)

Sacroiliitis (0-8)

5.0 (4-6)

5.0 (4-7)

m-SASSS (0-72)

2.5 (0-6)

1.6 (0-14)

BASRI-hip (0-8)

1.2 (0-2)

0.75 (0-2)


Values are presented as median (range). aDuration since diagnosis (in years), from definite ankylosing spondylitis (AS) diagnosis according to the modified New York criteria. bDuration of symptoms (in years), from the start of inflammatory back pain. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASRI-hip, Bath Ankylosing Spondylitis Index for the Hip (0 to 4, sum of right and left scores); ESR, erythrocyte sedimentation rate; HLA-B27, human leukocyte antigen-B27; m-SASSS, modified Stoke Ankylosing Spondylitis Spinal Score; Sacroiliitis, sacroiliitis scoring according to the radiographic modified New York criteria (0 to 4, sum of right and left scores).

Bruijnen et al. Arthritis Research & Therapy 2012 14:R71   doi:10.1186/ar3792

Open Data